|
|
Post by the Scribe on Jan 27, 2024 21:01:12 GMT
|
|
|
|
Post by the Scribe on Mar 10, 2024 16:37:38 GMT
Dr. Becker Discusses Pet Diarrhea
Dr. Karen Becker
143,896 views Feb 22, 2017
Dr. Karen Becker, a proactive and integrative wellness veterinarian, talks about the causes of diarrhea in pets, as well as the different symptoms and treatment.
healthypets.mercola.com/
Subscribe for the latest pet news and get recipes from my eBook for FREE:
Visit our website:
bit.ly/2KgUY0e
Listen to our podcasts:
bit.ly/2Qd3tgo
Spotify: spoti.fi/2QjF1tS
Find us on Social Media:
Facebook: / doctor.karen.becker
MeWe: mewe.com/p/dr.karenbecker
Instagram: / drkarenbecker
Twitter: / drkarenbecker |
|
|
|
Post by the Scribe on Mar 15, 2024 15:21:07 GMT
Beaumont researching way to stop C. difficile infections
Beaumont Health
3,320 views Dec 6, 2016
Beaumont researchers believe a drug called vancomycin, which is normally used to treat C. diff infections, can also keep the C. diff in check.
If successful, this research could potentially save thousands of lives, stop tens of thousands of infections and save millions of health care dollars.
Parenterally administered vancomycin in 29 dogs and 7 cats (2003‐2017)
www.ncbi.nlm.nih.gov/pmc/articles/PMC6335575/
Vancomycin is commonly used to treat resistant bacterial infections in people. Reported adverse effects of vancomycin in people include acute kidney injury (AKI), neutropenia, and systemic allergic reaction. Given the increased incidence of vancomycin‐resistant bacterial infections in people, support is growing for restriction of vancomycin.
Objectives
To evaluate the use of intravenous (IV) vancomycin in a university teaching hospital and to describe potential adverse effects.
Animals
Twenty‐nine dogs and 7 cats.
Methods
Medical records of dogs and cats treated with IV vancomycin at the Foster Hospital for Small Animals between January 2003 and October 2017 were reviewed. Information recorded included signalment, infection source, vancomycin dosing, potential adverse effects, and outcome.
Results
Vancomycin was used to treat infections from a range of sources with a variety of dosing intervals. The most common bacterial isolates susceptible to vancomycin included Enterococcus sp. (11/36, 30.6%), methicillin‐resistant Staphylococcus aureus (8/36, 22.2%), and methicillin‐resistant Staphylococcus pseudintermedius (2/36, 5.6%). AKI occurred in 6 of 36 patients (16.7%) during vancomycin treatment but could not definitively be attributed to vancomycin treatment in any patients because of illness severity, additional nephrotoxic treatments, or both. Neutropenia or allergic reaction was not documented in any animal. In 2 of 36 patients (5.6%), susceptibility data documented an infection that was only susceptible to vancomycin. Most patients survived to discharge (25/36, 69.4%).
Conclusions and Clinical Importance
Adverse effects attributable to vancomycin were infrequent in dogs and cats. In most cases, there were potential alternative effective antimicrobials or lack of susceptibility data to support vancomycin treatment.
Keywords: acute renal failure, antibiotic resistance, antibiotic stewardship, glycopeptide |
|
